Beroni Group

Beroni Group

Beroni Group was incorporated in 2008 and listed on the Australian Securities Exchange under the code BTG. Jacky Zhang, the founding Chairman and CEO, repositioned the firm after the 2016 public listing, moving the strategic center of gravity from importing and distributing consumer goods into oncology-focused biotechnology. The group now operates through subsidiaries developing chimeric antigen receptor natural killer (CAR-NK) cell therapies, alongside a molecular diagnostics division building rapid test platforms for cancer screening and infectious disease. Beroni maintains a physical presence in Sydney and New York, with research collaboration ties and patent filings concentrated in China, the United States, and Japan (per the firm's official communications). The firm's strategy rests on two linked verticals: a therapeutics pipeline targeting solid tumors and hematologic malignancies via allogeneic CAR-NK cells, and a diagnostics business producing point-of-care devices for early cancer detection. Beroni's lead therapeutic candidate targets pancreatic cancer — a notoriously difficult indication — while its diagnostic subsidiary has commercialized a Covid-19 antigen test kit and continues developing multi-cancer screening panels. The group holds a portfolio of patents covering cell culture methods, engineered receptor designs, and microfluidic detection technologies. Beroni's hybrid model combines in-house R&D with partnerships at Chinese hospitals and universities, a sourcing approach that bypasses traditional venture-fund intermediation. Beroni's team size and total deployment remain undisclosed, but the firm's public filings confirm joint ventures and subsidiary relationships in Tianjin, China, for therapeutic manufacturing and in the US for diagnostic distribution. In February 2022, Beroni announced a research collaboration with a Chinese university to advance its CAR-NK pancreatic cancer program (per the firm, February 2022). The group also maintains a legacy trading business — a structural remnant from its pre-2016 operating history — which occasionally surfaces in quarterly cash-flow statements but is no longer the driver of market capitalization. Beroni's architecture blends a public-company governance framework with a venture-stage biotech risk profile — an unusual combination for an ASX-listed entity. The public listing provides a currency for acquisitions and licensing deals without the fund-life constraints of a venture capital partnership, but it also exposes the firm to quarterly reporting pressures atypical for early-stage drug developers. This structural twist means allocators evaluating Beroni must assess it as an operating company with a binary drug-development outcome, not as a diversified fund vehicle.